Innate immune response to interferon gamma in severe Covid-19 positive patients
Main Article Content
Keywords
COVID-19, Immunity, Interferon-gamma
Abstract
Abstract
Background: SARS-CoV-2 is associated with the activation of innate immunity, with an observed increase in neutrophils, mononuclear phagocytes, and natural killer cells, as well as a decrease in T. Gamma interferon (IFN-γ) is a cytokine that plays a fundamental role in maintaining homeostasis in the body, both in vitro and in vivo.
Objective: An immunological study was conducted to measure the concentrations of IFN-γ in severe SARS-CoV-2-positive patients.
Material and methods: Around 500 sera from patients with similar respiratory comorbidities at the onset of the disease were analyzed, using healthy patients as controls. The sera from SARS-CoV-2-positive individuals were processed using the ELISA technique, and the statistical treatment of the data involved creating a database with the absorbance readings, which were then converted into concentrations in pg/ml.
Results: We can infer that the amount of IFN-γ expression depends on the patient’s condition; the more severe the patient’s condition, the higher the expression of this cytokine compared to their baseline levels, ranging from 0 to 0.5 μg/ml.
Conclusion: It is suggested that the IFN-γ response plays an important role in controlling the disease, and effective therapies are recommended for the treatment of Covid-19, which will lead to the implementation of therapeutic approaches aimed at counteracting the immune system, especially in the more severe forms of the disease.
References
Senevirathne TH, Wekking D, Swain JWR, et al. COVID-19: From emerging variants to vaccination. Cytokine Growth Factor Rev. 2024;76:127-41.
Yüce M, Filiztekin E, Özkaya KG. COVID-19 diagnosis -A review of current methods. Biosens Bioelectron. el 15 de enero de 2021;172:112752.
Beladiya J, Kumar A, Vasava Y, Parmar K, et al. Safety and efficacy of COVID-19 vaccines: A systematic review and meta-analysis of controlled and randomized clinical trials. Rev Med Virol. 2024;34(1):e2507.
Krammer F. The role of vaccines in the COVID-19 pandemic: what have we learned? Semin Immunopathol. 2024;45 (4-6):451-68.
Villalobos-Gómez FDR, García-Lorenzana M, Escobedo G, et al. Entamoeba histolytica L220 induces the in vitro activation of macrophages and neutrophils and is modulated by neurotransmitters. Acta Parasitol. 2018;63(2):270-9.
Anjum FR, Anam S, Abbas G, et al. Type I IFNs: A Blessing in Disguise or Partner in Crime in MERS-CoV-, SARS-CoV-, and SARS-CoV-2-Induced Pathology and Potential Use of Type I IFNs in Synergism with IFN- γ as a Novel Antiviral Approach Against COVID-19. Viral Immunol. 2021;34(5):321-9.
Liu W, Zhang S, Wang J. IFN-γ, should not be ignored in SLE. Front Immunol. 2022;13:954706.
Yasukawa K, Saito S, Kubo T, et al. Low-dose recombinant canine interferon-gamma for treatment of canine atopic dermatitis: an open randomized comparative trial of two doses. Vet Dermatol. 2010;21(1):42-9.
Alspach E, Lussier DM, Schreiber RD. Interferon γ and Its Important Roles in Promoting and Inhibiting Spontaneous and Therapeutic Cancer Immunity. Cold Spring Harb Perspect Biol. e2019;11(3):a028480.
Fernández-Rúa JM. Interferón: Hallazgo clave contra infección por coronavirus. biotechmagazineandnews.com. 2020 [citado el 25 de abril de 2020]. Disponible en: https://biotechmagazineandnews.com/interferon-hallazgo-clave-contra-infeccion-por-coronavirus/
Cantell K, Pirhonen J. IFN-gamma enhances production of IFN-alpha in human macrophages but not in monocytes. J Interferon Cytokine Res Off J Int Soc Interferon Cytokine Res. 1996;16(6):461-3.
Ikeda H, Old LJ, Schreiber RD. The roles of IFN gamma in protection against tumor development and cancer immunoediting. Cytokine Growth Factor Rev. 2002;13(2):95-109.
Chen G, Wu D, Guo W, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest. 2020;130(5):2620-2629.
Cremoni M, Allouche J, Graça D, et al. Low baseline IFN-γ response could predict hospitalization in COVID-19 patients. Front Immunol. 2022;13:953502.
Fess LJ, Fell A, O’Toole S, et al. COVID-19 Death Determination Methods, Minnesota, USA, 2020-20221. Emerg Infect Dis. 2024;30(7):1352-60.
Huang TC, Liang KH, Chang TJ, et al. Structure-based approaches against COVID-19. J Chin Med Assoc. 2024;87(2): 139.
Hein J, Schellenberg U, Bein G, et al. Quantification of murine IFN-gamma mRNA and protein expression: impact of real-time kinetic RT-PCR using SYBR green I dye. Scand J Immunol. 2001;54(3):285-91.
Palacios-Cruz M, Santos E, Velázquez-Cervantes MA, et al. COVID-19, a worldwide public health emergency. Rev Clin Esp. 2021;221(1):55-61.
Mata-Espinosa DA, Hernández-Pando R. Interferón gamma: aspectos básicos, importancia clínica y usos terapéuticos. Rev Investig Clínica. 2008;60(5):421-31.
Sposito B, Broggi A, Pandolfi L, et al. The interferon landscape along the respiratory tract impacts the severity of COVID-19. Cell. 2021;184(19):4953-4968.e16.
Gocher AM, Workman CJ, Vignali DAA. Interferon-γ: team-mate or opponent in the tumour microenvironment? Nat Rev Immunol. 2022;22(3):158-72.
Viox EG, Bosinger SE, Douek DC, et al. Harnessing the power of IFN for therapeutic approaches to COVID-19. J Virol. 2024;98(5):e01204-23.
Mansoor S, Butt AR, Bibi A, et al. Expression of IFN-Gamma is significantly reduced during severity of covid-19 infection in hospitalized patients. PloS One. 2023;18(9):e0291332.
González-Sánchez N, Armada-Esmores Z, Llópiz-Casanova L. Propiedades de los interferones y su acción antitumoral. 2017;21(3). Disponible en: http://scielo.sld.cu/scielo. php?script=sci_arttext&pid=S1029-30432017000300002
Ivashkiv LB. IFNγ: signalling, epigenetics and roles in immunity, metabolism, disease and cancer immunotherapy. Nat Rev Immunol. 2018;18(9):545–58.
de Castro GS, Gama LR, Ramos AF, et al. Post-COVID-19 condition: systemic inflammation and low functional exercise capacity. Front Nutr. 2024;11:1295026.
Choi HS, Choi AY, Kopp JB, et al. Review of COVID-19 Therapeutics by Mechanism: From Discovery to Approval. J Korean Med Sci. 2024;39(14):e134.
Wang C, Wang X, Zhang S, et al. Causal relationships between interleukins, interferons and COVID-19 risk: a Mendelian randomization study. Int J Environ Health Res. 2024;34 (5):2387–96.
Ng CT, Fong LY, Abdullah MNH. Interferon-gamma (IFN-γ): Reviewing its mechanisms and signaling pathways on the regulation of endothelial barrier function. Cytokine. 2023; 166:156208.
Todorović-Raković N, Whitfield JR. Between immunomodulation and immunotolerance: The role of IFNγ in SARS-CoV-2 disease. Cytokine. 2021;146:155637.
Article Sidebar
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Authors retain their copyright and grant the Revista Médica del IMSS the right of first publication. Articles are distributed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which allows sharing as long as the author and the original source are properly credited.